The general field of this disclosure is systems and devices related to managing a user's respiratory condition.
Spirometers are often used to diagnose a variety of chronic lung conditions, such as asthma and chronic obstructive pulmonary disease (“COPD”), that may require the use of control and rescue inhalers. To complete a spirometer maneuver, many current spirometers require a user to attempt to use full tidal volume of their lungs and blow through a wide hole. Such a maneuver can result in coughing and general discomfort. Additionally, treatment of chronic lung conditions may require users carry around a number of items, including rescue medication, control medication, inhaler, spirometer, and a tracking device.
In some aspects of the disclosure, a spirometer-inhaler device for managing a user's respiratory condition is disclosed. A spirometer-inhaler device can include: a first portion that can removably receive a medicine canister; a second portion that can extend from the first portion and include a mouthpiece; a first flow path that can direct medication from the medicine canister to the opening of the mouthpiece; and a second flow path that can direct exhaled air from the opening of the mouthpiece to one or more flow rate measurement devices. The mouthpiece can include an opening and one or more propellers. The second flow path can include one of the one or more propellers.
In some aspects, the first portion can include a central cavity that can removably receive the medicine canister.
In some aspects, the first portion can optionally include a one way valve that can removably connect to the medicine canister and direct medication from the medicine canister to the opening of the mouthpiece.
In some aspects, the first flow path can include the one way valve and the opening of the mouthpiece.
In some aspects, the one way valve can form a seal with the medicine canister.
In some aspects, the seal can prevent the exhaled air from entering the first flow path.
In some aspects, the one way valve can deliver the medication from the medicine canister to the opening of the mouthpiece via the first flow path.
In some aspects, the first portion may not include a valve. For example, the first portion may include an interior gap that can direct medication from the medicine canister to the opening of the mouthpiece.
In some aspects, the spirometer-inhaler device can further include an interior flow pathway with a first end and a second end.
In some aspects, the second flow path can include the interior flow pathway and the opening of the mouthpiece.
In some aspects, the first end of the interior flow pathway can be located adjacent the opening of the mouthpiece. The second end of the interior flow pathway can be located on a side portion of the first portion.
In some aspects, the second flow path can further include at least one cover.
In some aspects, the at least one cover can include at least one shutter. The at least one shutter can include a lever portion and a cover portion that can cover the second end of the interior flow pathway.
In some aspects, the cover portion of the at least one shutter can be removed from the second end of the interior flow pathway in response to a user actuating the lever portion of the at least one shutter.
In some aspects, the at least one cover can include one or more of: a manual plug, a rotatable cover, a mechanical iris, or a cuspid one-way valve.
In some aspects, the interior flow pathway can include an interior tube.
In some aspects, the interior flow pathway can include a plurality of interior ribs. The plurality of interior ribs can guide the second flow path from the opening of the mouthpiece to the second end of the plurality of interior ribs.
In some aspects, the second end of the interior flow pathway can removably connect to the one or more flow rate measurement devices.
In some aspects, the spirometer-inhaler device can further include a display.
In some aspects, the display can be disposed on the first portion.
In some aspects, the spirometer-inhaler can further include at least one processor that can estimate one or more physiological parameters of the user based on measurements from the device.
In some aspects, the spirometer-inhaler device can further include a transmitter.
In some aspects, the transmitter can transmit the one or more physiological parameters of the user to one or more of: a network, a backend system, or one or more user devices.
In some aspects, the first flow path can include a propeller of the one or more propellers.
In some aspects, the propeller can be positioned adjacent the opening of the mouthpiece.
In some aspects, the propeller can spin in response to a negative flow rate within the mouthpiece.
In some aspects, the at least one processor can begin taking measurements in response to the propeller spinning.
In some aspects, the negative flow rate can be created within the mouthpiece by the user inhaling from the opening of the mouthpiece in use.
In some aspects, a propeller of the one or more propellers can be operatively connected to a turbine.
In some aspects of the disclosure, a system for delivering a medication to a user and measuring a plurality of physiological parameters of the user is disclosed. The system can include: a spirometer-inhaler device; a medicine canister that can deliver the medication to a first portion of the spirometer-inhaler device; and one or more measurement devices that can estimate one or more physiological parameters of the user. The spirometer-device can include: the first portion that can removably receive the medicine canister; a second portion that can extend from the first portion and include a mouthpiece that can include an opening and one or more propellers; a first flow path that can direct the medication from the medicine canister to the opening of the mouthpiece; and a second flow path that can direct exhaled air from the opening of the mouthpiece to one or more flow rate measurement devices. The second flow path can include one of the one or more propellers. The one or more measurement devices can include the one or more flow rate measurement devices.
In some aspects, the spirometer-inhaler device can further include a central hole that can removably receive the medicine canister.
In some aspects, the spirometer-inhaler device can further include a one way valve that can removably connect to the medicine canister and direct medication from the medicine canister to the opening of the mouthpiece.
In some aspects, the medicine canister can deliver the medication to the one way valve.
In some aspects, the first flow path can include the one way valve and the opening of the mouthpiece.
In some aspects, the central hole of the first portion can include an internal gap. The internal gap can direct medication from the medicine canister to the opening of the mouthpiece.
In some aspects, the spirometer-inhaler device can further include an interior flow pathway with a first end and a second end.
In some aspects, the first end of the interior flow pathway can be located adjacent the opening of the second portion and the second end of the interior flow pathway can be located on a side portion of the first portion.
In some aspects, the second flow path can include the interior flow pathway and the opening of the mouthpiece.
In some aspects, the second end of the interior flow pathway can be connectable to the one or more flow rate measurement devices.
In some aspects, the interior flow pathway can include one or more of: one or more interior tubes or one or more interior ribs.
In some aspects, the one or more flow rate measurement devices can estimate at least one of: forced inspiratory flow, force expiratory volume, forced expiratory flow, force vital capacity, maximal voluntary ventilation, inspiratory reserve volume, expiratory reserve volume, residual volume, functional residual capacity, total lung capacity, inspiratory capacity, tidal volume, vital capacity, maximal inspiratory pressure, or maximal expiratory pressure.
In some aspects, the one or more flow rate measurement devices can be connectable to the second flow path.
In some aspects, the one or more measurement devices can measure at least one of: oxygen saturation, respiratory rate, total hemoglobin level, level of carboxyhemoglobin, level of methemoglobin, pulse rate, or acoustic measurements.
In some aspects, the system can further include a display.
In some aspects, the display can be disposed on one or more of: the spirometer-inhaler device, the one or more measurement devices, or one or more user devices.
In some aspects, the system can further include a transmitter.
In some aspects, the transmitter can transmit the one or more physiological parameters of the user to one or more of: a network, a backend system, or one or more user devices.
The following drawings and the associated descriptions are provided to illustrate embodiments of the present disclosure and do not limit the scope of the claims.
Aspects of the disclosure will now be set forth in detail with respect to the figures and various examples. One of skill in the art will appreciate, however, that other configurations of the devices and methods disclosed herein will still fall within the scope of this disclosure even if not described in the same detail. Aspects of various configurations discussed do not limit the scope of the disclosure herein, which is instead defined by the claims following this description.
The one or more user devices 406 can include a device associated with the user 402 of the one or more data collection devices 404, a device associated with a health care provider, a device associated with a third-party user, a device associated with a user's employer, the like or a combination thereof. For example, a user may measure the user's FIF value with the spirometer-inhaler device 100 and the spirometer-inhaler device 100 may transmit the user's estimated FIF value to the health care provider's device(s) so that the health care provider can monitor the user's respiratory health. Additionally, or alternatively, the device 100 can communicate the user's FIF value to the user's phone to display the user's FIF value on the phone's display and store the FIF value in the phone's memory so that the user can monitor the user's own respiratory health. For example, the user may download a mobile application associated with the spirometer-inhaler device 100 onto the user's phone or smartwatch. In order to access the user's respiratory health data, the user may access the mobile application and view the different physiological parameters being measured by the device 100 or the spirometer-inhaler system 200, as described below in reference to
The data collected by the spirometer-inhaler device 100, and the one or more data collection devices 404 can include a plurality of data associated with the user, including but not limited to health data. In some examples, health data can include heart rate, blood pressure, glucose, VO2 maximum, oxygen saturation, respiration rate, total hemoglobin levels, carboxyhemoglobin levels, methemoglobin levels, pulse-rate, pulmonary vascular resistance, symptoms and their severity, FIF, Force Expiratory Volume (FEV1), Forced Expiratory Flow (FEF), the like or a combination thereof. This collected data can be processed in a variety of different ways. For example, the spirometer-inhaler device 100 may include a processor that estimates a user's FIF value based on the user blowing into the device 100. The spirometer-inhaler device 100 may store the FIF data on a memory of the device 100 and display the FIF value on a display of the device 100. Additionally, or alternatively, the device 100 may send a measured value to a second device or the backend system 410, which processes the measured value to estimate a FIF value. The second device may display the estimated FIF value or the second device may send the FIF value to the device 100 so that the device 100 displays the FIF value.
In some aspects, the spirometer-inhaler device 100 may include a first portion 110 and a second portion 112. In some embodiments, the device 100 may include a general L-shape, similar to a standard inhaler, with the first portion 110 forming the vertical component and the second portion 112 forming the horizontal component. Although the device 100 is shown as including a general L-shape, other shapes are contemplated. For example, the device may be cylindrical, conical, spherical, or have another shape in whole or in part. The first portion 110 may include a one-way valve 120, a first end 122 including a top opening, and a central cavity. The central cavity of the first portion 110 can extend from the first end 122 through the center of the first portion 110 and be configured to removably receive the canister 300. In some aspects, the first portion 110 itself can be one of the two (or more) channels required for flow estimations. The first portion 110 can have a one-way valve 120 (such as illustrated in
In some aspects, the second portion 112 of the device 100 may extend from the first portion 110, adjacent a second end 126 of the first portion 110 opposite the first end 122. The second portion 112 may include a mouth piece 112 with an opening 114 and at least one propeller 116, 118. In some embodiments, the system 200 may include a turbine with a turning wheel. In some embodiments, the system 200 includes the canister 300. The canister 300 may be a medicine canister that holds control medication, rescue medication, or the like.
In some configurations, the disclosed system 200 can include two or more flow paths 104, 106. A first flow path 106 of the two or more flow paths may include the canister 300, the one-way valve 120 of the first portion 110, and/or the second portion 112. The direction of the first flow path 106 is indicated by arrow 106 in
In some configurations, the spirometer-inhaler system 200 can take additional measurements to enable better predictive capacity of FEV1 or FEF. For example, the system 200 can utilize the patient's inhalation to better estimate common respiratory measurements. Moreover, the system 200 can use additional measurements, such as oxygen saturation, respiration rate, and the like, to improve the estimation of all variable types listed in the present disclosure. For example, these additional measurements can be utilized as spot-check, trended, or modeled forms of these data types.
In some configurations, the system 200 includes a second flow path 104 that may include portions of the second portion 120. The direction of the second flow path 104 is indicated by arrow 104 in
In some aspects, the second end 130 of the interior flow pathway 124 is configured to be removably connected to the one or more flow measurement devices. The one or more flow measurement devices can include devices that measure FT values, FEV1 values or FEF values. When the one or more flow measurement devices are connected to the interior flow pathway 124, the second flow path 104 may include the one of the one or more flow measurement devices.
The interior flow pathway 124 may include a hole, which extends from the first end 128 of the interior flow pathway 124 to the second end 130 of the interior flow pathway 124, that may be smaller than the wider standard holes of current spirometers. For example, the hole of the interior flow pathway 124 can be approximately half to a quarter of the size of the wider standard holes of current spirometers.
As described above, the system 200 can comprise one or more processors. The processor(s) may be located within the spirometer-inhaler device 100, the one or more flow measurement devices, and/or the backend system 410. In some embodiments, the processor(s) can be configured to extrapolate the measurements from the smaller hole of the interior flow pathway 124 to assess the air flow of the wider standard holes of current spirometers. The smaller hole enables the prediction of FIF, FEV1 or FEF without requiring the user to completely expel the air (or completely deplete the air) from their lungs. Advantageously, reducing the amount of lung depletion may improve user comfort. In some configurations, the processor may also be configured to upload, download, display, analyze, read, write, access, or otherwise interact with the data or information associated with the user, such as data collected by the one or more data collection device 404 including the device 100 and/or the one or more flow measurement devices, or other information associated with displaying and/or analyzing the data or information associated with the user.
Additionally or alternatively, the one or more processors of the system 200 may estimate biometric parameters other than FIF, FEV1, or FEF, including, but not limited to, Force Vital Capacity (FVC), Maximal Voluntary Ventilation (MVV), Inspiratory Reserve Volume (IRV), Expiratory Reserve Volume (ERV), Residual Volume (RV), Functional Residual Capacity (FRC), Total Lung Capacity (TLC), IC (Inspiratory Capacity), tidal volume, vital capacity, and Maximal Inspiratory Pressure (MIP), and Maximal Expiratory Pressure (MEP). To effectively estimate some of these other values, the user may have to deplete their lungs.
In some aspects, the second flow path 104 may include a turbine with a first end and a second end. The first end of the turbine can include a turning wheel that can be adapted to cause the airflow that passes through the turning wheel to rotate helically. The turbine can also include a vane between the turning wheel and the second end of the turbine. The helically rotating airflow can cause the internal vane to rotate. The rotations of the internal vane can be detected by a sensor which can send the sensor signals to the one or more processors. The processor(s) can determine certain physiological parameters related to a patient's lung functionality. For example, the processor(s) can determine a user's FIF, FEV1 and/or FEF values.
In some embodiments, the system 200 may comprise a memory configured to store user's instructions. For example, one or more processors of the system 200 may access the user's instructions from the memory and display the instructions on a display of the system 200. The user's instructions may instruct the user on how to measure different physiological parameters with the system 200. For example, if the user wants to measure the user's FVC value, the user's instructions may include instructing the user to deplete the user's lungs into the device 100. Additionally or alternatively, the user can access the user's instructions on the user's phone via the mobile application associated with the spirometer-inhaler device 100. In some aspects, the user can access the user's instructions on any of the user devices 406 via an application, a website, or the like.
In some configurations, the spirometer-inhaler system 200 may further include a display (not shown) configured to display relevant information, one or more sensors, a battery, and a transmitter. In some aspects, the display can be positioned on the spirometer-inhaler device 100 and be electronically connected to the battery and the one or more processors. Additionally or alternatively, the display may be positioned on the one or more user devices 406 and/or the one or more flow measurement devices. For example, when a user blows into the device 100, the display can show the estimated FIF value. In some embodiments, the device 100 may include one or more sensors that can be electronically connected to the one or more processors and the battery. Additionally or alternatively, the one or more sensors may be located within the one or more flow measurement devices. The one or more sensors may include one or more differential pressure sensors.
In some configurations, the transmitter that can be electronically connected to the battery and the one or more processors. Additionally or alternatively, the transmitter may be located within the one or more flow measurement devices. In some aspects, the transmitter may be configured to transmit the health data from the device 100 or the one or more flow measurement devices to the network 408, the back end system 410, and/or the one or more user devices 406.
In some embodiments, one or more covers 108 may be incorporated in the second flow path 104 to enable switching between the one or more flow measurement devices. For example, the one or more covers 108 can include one or more shutters 108 with a lever portion 132 connected to a cover portion 134 configured to cover the second end 130 of the interior flow pathway 124. The user can push on the lever portion 132 removing the cover portion 134 from the second end 130 of the interior flow pathway 124, thereby opening the second flow path 104. With the second flow path 104 open, the user can removably connect an external device to the second flow path 104. The external device, for example, can include the one or more flow measurement devices. Additionally, or alternatively, the one or more covers 108 may include a manual plug, a cover adapted to open and close via a rotation mechanism, a mechanical iris, a cuspid one-way valve, a flap, or the like.
Conditional language used herein, such as, among others, “can,” “could,” “might,” “may,” “e.g.,” and the like, unless specifically stated otherwise, or otherwise understood within the context as used, is generally intended to convey that certain, certain features, elements and/or steps are optional. Thus, such conditional language is not generally intended to imply that features, elements and/or steps are in any way required or that one or more implementations necessarily include logic for deciding, with or without other input or prompting, whether these features, elements and/or steps are included or are to be always performed. The terms “comprising,” “including,” “having,” and the like are synonymous and are used inclusively, in an open-ended fashion, and do not exclude additional elements, features, acts, operations, and so forth. Also, the term “or” is used in its inclusive sense (and not in its exclusive sense) so that when used, for example, to connect a list of elements, the term “or” means one, some, or all of the elements in the list.
Conjunctive language such as the phrase “at least one of X, Y, and Z,” unless specifically stated otherwise, is otherwise understood with the context as used in general to convey that an item, term, etc. may be either X, Y, or Z. Thus, such conjunctive language is not generally intended to imply that certain implementations require the presence of at least one of X, at least one of Y, and at least one of Z.
Language of degree used herein, such as the terms “approximately,” “about,” “generally,” and “substantially” as used herein represent a value, amount, or characteristic close to the stated value, amount, or characteristic that still performs a desired function or achieves a desired result. For example, the terms “approximately”, “about”, “generally,” and “substantially” may refer to an amount that is within less than 10% of, within less than 5% of, within less than 1% of, within less than 0.1% of, and within less than 0.01% of the stated amount. As another example, in certain implementations, the terms “generally parallel” and “substantially parallel” refer to a value, amount, or characteristic that departs from exactly parallel by less than or equal to 15 degrees, 10 degrees, 5 degrees, 3 degrees, 1 degree, 0.1 degree, or otherwise.
Any methods disclosed herein need not be performed in the order recited. The methods disclosed herein include certain actions taken by a practitioner; however, they can also include any third-party instruction of those actions, either expressly or by implication.
The methods and tasks described herein may be performed and fully automated by a computer system. The computer system may, in some cases, include multiple distinct computers or computing devices (for example, physical servers, workstations, storage arrays, cloud computing resources, etc.) that communicate and interoperate over a network to perform the described functions. Each such computing device typically includes a processor (or multiple processors) that executes program instructions or modules stored in a memory or other non-transitory computer-readable storage medium or device (for example, solid state storage devices, disk drives, etc.). The various functions disclosed herein may be embodied in such program instructions, and/or may be implemented in application-specific circuitry (for example, ASICs or FPGAs) of the computer system. Where the computer system includes multiple computing devices, these devices may, but need not, be co-located. The results of the disclosed methods and tasks may be persistently stored by transforming physical storage devices, such as solid state memory chips and/or magnetic disks, into a different state. The computer system may be a cloud-based computing system whose processing resources are shared by multiple distinct business entities or other users.
Depending on the implementation, certain acts, events, or functions of any of the processes or algorithms described herein can be performed in a different sequence, can be added, merged, or left out altogether (for example, not all described operations or events are necessary for the practice of the algorithm). Moreover, in certain implementations, operations or events can be performed concurrently, for example, through multi-threaded processing, interrupt processing, or multiple processors or processor cores or on other parallel architectures, rather than sequentially.
The various illustrative logical blocks, modules, routines, and algorithm steps described in connection with the disclosure herein can be implemented as electronic hardware (for example, ASICs or FPGA devices), computer software that runs on general purpose computer hardware, or combinations of both. Various illustrative components, blocks, and steps have been described above generally in terms of their functionality. Whether such functionality is implemented as specialized hardware versus software running on general-purpose hardware depends upon the particular application and design constraints imposed on the overall system. The described functionality can be implemented in varying ways for each particular application, but such implementation decisions should not be interpreted as causing a departure from the scope of the disclosure.
Moreover, the various illustrative logical blocks and modules described in connection with the disclosure herein can be implemented or performed by a machine, such as a general purpose processor device, a digital signal processor (DSP), an application specific integrated circuit (ASIC), a field programmable gate array (FPGA) or other programmable logic device, discrete gate or transistor logic, discrete hardware components, or any combination thereof designed to perform the functions described herein. A general purpose processor device can be a microprocessor, but in the alternative, the processor device can be a controller, microcontroller, or state machine, combinations of the same, or the like. A processor device can include electrical circuitry configured to process computer-executable instructions. A processor device can include an FPGA or other programmable device that performs logic operations without processing computer-executable instructions. A processor device can also be implemented as a combination of computing devices, for example, a combination of a DSP and a microprocessor, a plurality of microprocessors, one or more microprocessors in conjunction with a DSP core, or any other such configuration. Although described herein primarily with respect to digital technology, a processor device may also include primarily analog components. For example, some or all of the rendering techniques described herein may be implemented in analog circuitry or mixed analog and digital circuitry. A computing environment can include any type of computer system, including, but not limited to, a computer system based on a microprocessor, a mainframe computer, a digital signal processor, a portable computing device, a device controller, or a computational engine within an appliance, to name a few.
The elements of a method, process, routine, or algorithm described in connection with the disclosure herein can be embodied directly in hardware, in a software module executed by a processor device, or in a combination of the two. A software module can reside in RAM memory, flash memory, ROM memory, EPROM memory, EEPROM memory, registers, hard disk, a removable disk, a CD-ROM, or any other form of a non-transitory computer-readable storage medium. An exemplary storage medium can be coupled to the processor device such that the processor device can read information from, and write information to, the storage medium. In the alternative, the storage medium can be integral to the processor device. The processor device and the storage medium can reside in an ASIC. The ASIC can reside in a user terminal. In the alternative, the processor device and the storage medium can reside as discrete components in a user terminal.
While the above detailed description has shown, described, and pointed out novel features, it can be understood that various omissions, substitutions, and changes in the form and details of the devices or algorithms illustrated can be made without departing from the spirit of the disclosure. As can be recognized, certain portions of the description herein can be embodied within a form that does not provide all of the features and benefits set forth herein, as some features can be used or practiced separately from others. The scope of certain implementations disclosed herein is indicated by the appended claims rather than by the foregoing description. All changes which come within the meaning and range of equivalency of the claims are to be embraced within their scope.
This application claims the benefit of priority to U.S. Provisional App. No. 63/044,269 entitled “COMBINATION SPIROMETER-INHALER,” filed Jun. 25, 2020 and U.S. Provisional App. No. 63/071,310 entitled “COMBINATION SPIROMETER-INHALER,” filed Aug. 27, 2020. Each of these applications are hereby incorporated by reference herein in their entireties. Any and all applications for which a foreign or domestic priority claim is identified in the Application Data Sheet as filed with the present application are hereby incorporated by reference and made a part of the present disclosure.
Number | Name | Date | Kind |
---|---|---|---|
492973 | Shepard | Mar 1893 | A |
895606 | Warde | Aug 1908 | A |
4148308 | Sayer | Apr 1979 | A |
4960128 | Gordon et al. | Oct 1990 | A |
4964408 | Hink et al. | Oct 1990 | A |
5319355 | Russek | Jun 1994 | A |
5337744 | Branigan | Aug 1994 | A |
5341805 | Stavridi et al. | Aug 1994 | A |
D353195 | Savage et al. | Dec 1994 | S |
D353196 | Savage et al. | Dec 1994 | S |
5377676 | Vari et al. | Jan 1995 | A |
D359546 | Savage et al. | Jun 1995 | S |
5431170 | Mathews | Jul 1995 | A |
5436499 | Namavar et al. | Jul 1995 | A |
D361840 | Savage et al. | Aug 1995 | S |
D362063 | Savage et al. | Sep 1995 | S |
D363120 | Savage et al. | Oct 1995 | S |
5456252 | Vari et al. | Oct 1995 | A |
5479934 | Imran | Jan 1996 | A |
5482036 | Diab et al. | Jan 1996 | A |
5494043 | O'Sullivan et al. | Feb 1996 | A |
5533511 | Kaspari et al. | Jul 1996 | A |
5561275 | Savage et al. | Oct 1996 | A |
5590649 | Caro et al. | Jan 1997 | A |
5602924 | Durand et al. | Feb 1997 | A |
5638816 | Kiani-Azarbayjany et al. | Jun 1997 | A |
5638818 | Diab et al. | Jun 1997 | A |
5645440 | Tobler et al. | Jul 1997 | A |
5671914 | Kalkhoran et al. | Sep 1997 | A |
5724986 | Jones et al. | Mar 1998 | A |
5726440 | Kalkhoran et al. | Mar 1998 | A |
D393830 | Tobler et al. | Apr 1998 | S |
5743262 | Lepper, Jr. et al. | Apr 1998 | A |
5747806 | Khalil et al. | May 1998 | A |
5750994 | Schlager | May 1998 | A |
5758644 | Diab et al. | Jun 1998 | A |
5760910 | Lepper, Jr. et al. | Jun 1998 | A |
5890929 | Mills et al. | Apr 1999 | A |
5919134 | Diab | Jul 1999 | A |
5987343 | Kinast | Nov 1999 | A |
5997343 | Mills et al. | Dec 1999 | A |
6002952 | Diab et al. | Dec 1999 | A |
6010937 | Karam et al. | Jan 2000 | A |
6027452 | Flaherty et al. | Feb 2000 | A |
6040578 | Malin et al. | Mar 2000 | A |
6066204 | Haven | May 2000 | A |
6115673 | Malin et al. | Sep 2000 | A |
6124597 | Shehada et al. | Sep 2000 | A |
6128521 | Marro et al. | Oct 2000 | A |
6129675 | Jay | Oct 2000 | A |
6144868 | Parker | Nov 2000 | A |
6152754 | Gerhardt et al. | Nov 2000 | A |
6184521 | Coffin, IV et al. | Feb 2001 | B1 |
6232609 | Snyder et al. | May 2001 | B1 |
6241683 | Macklem et al. | Jun 2001 | B1 |
6255708 | Sudharsanan et al. | Jul 2001 | B1 |
6280381 | Malin et al. | Aug 2001 | B1 |
6285896 | Tobler et al. | Sep 2001 | B1 |
6308089 | von der Ruhr et al. | Oct 2001 | B1 |
6317627 | Ennen et al. | Nov 2001 | B1 |
6321100 | Parker | Nov 2001 | B1 |
6334065 | Al-Ali et al. | Dec 2001 | B1 |
6358058 | Strupat | Mar 2002 | B1 |
6360114 | Diab et al. | Mar 2002 | B1 |
6368283 | Xu et al. | Apr 2002 | B1 |
6411373 | Garside et al. | Jun 2002 | B1 |
6415167 | Blank et al. | Jul 2002 | B1 |
6430437 | Marro | Aug 2002 | B1 |
6430525 | Weber et al. | Aug 2002 | B1 |
6463311 | Diab | Oct 2002 | B1 |
6470199 | Kopotic et al. | Oct 2002 | B1 |
6487429 | Hockersmith et al. | Nov 2002 | B2 |
6505059 | Kollias et al. | Jan 2003 | B1 |
6525386 | Mills et al. | Feb 2003 | B1 |
6526300 | Kiani et al. | Feb 2003 | B1 |
6534012 | Hazen et al. | Mar 2003 | B1 |
6542764 | Al-Ali et al. | Apr 2003 | B1 |
6580086 | Schulz et al. | Jun 2003 | B1 |
6584336 | Ali et al. | Jun 2003 | B1 |
6587196 | Stippick et al. | Jul 2003 | B1 |
6587199 | Luu | Jul 2003 | B1 |
6595316 | Cybulski et al. | Jul 2003 | B2 |
6597932 | Tian et al. | Jul 2003 | B2 |
6606511 | Ali et al. | Aug 2003 | B1 |
6635559 | Greenwald et al. | Oct 2003 | B2 |
6639668 | Trepagnier | Oct 2003 | B1 |
6640116 | Diab | Oct 2003 | B2 |
6640117 | Makarewicz et al. | Oct 2003 | B2 |
6658276 | Kiani et al. | Dec 2003 | B2 |
6661161 | Lanzo et al. | Dec 2003 | B1 |
6697656 | Al-Ali | Feb 2004 | B1 |
6697658 | Al-Ali | Feb 2004 | B2 |
RE38476 | Diab et al. | Mar 2004 | E |
RE38492 | Diab et al. | Apr 2004 | E |
6738652 | Mattu et al. | May 2004 | B2 |
6760607 | Al-Ali | Jul 2004 | B2 |
6788965 | Ruchti et al. | Sep 2004 | B2 |
6816241 | Grubisic | Nov 2004 | B2 |
6822564 | Al-Ali | Nov 2004 | B2 |
6850787 | Weber et al. | Feb 2005 | B2 |
6850788 | Al-Ali | Feb 2005 | B2 |
6876931 | Lorenz et al. | Apr 2005 | B2 |
6920345 | Al-Ali et al. | Jul 2005 | B2 |
6934570 | Kiani et al. | Aug 2005 | B2 |
6943348 | Coffin, IV | Sep 2005 | B1 |
6956649 | Acosta et al. | Oct 2005 | B2 |
6961598 | Diab | Nov 2005 | B2 |
6970792 | Diab | Nov 2005 | B1 |
6985764 | Mason et al. | Jan 2006 | B2 |
6990364 | Ruchti et al. | Jan 2006 | B2 |
6998247 | Monfre et al. | Feb 2006 | B2 |
7003338 | Weber et al. | Feb 2006 | B2 |
7015451 | Dalke et al. | Mar 2006 | B2 |
7027849 | Al-Ali | Apr 2006 | B2 |
D526719 | Richie, Jr. et al. | Aug 2006 | S |
7096052 | Mason et al. | Aug 2006 | B2 |
7096054 | Abdul-Hafiz et al. | Aug 2006 | B2 |
D529616 | Deros et al. | Oct 2006 | S |
7133710 | Acosta et al. | Nov 2006 | B2 |
7142901 | Kiani et al. | Nov 2006 | B2 |
7225006 | Al-Ali et al. | May 2007 | B2 |
RE39672 | Shehada et al. | Jun 2007 | E |
7254429 | Schurman et al. | Aug 2007 | B2 |
7254431 | Al-Ali et al. | Aug 2007 | B2 |
7254434 | Schulz et al. | Aug 2007 | B2 |
7274955 | Kiani et al. | Sep 2007 | B2 |
D554263 | Al-Ali et al. | Oct 2007 | S |
7280858 | Al-Ali et al. | Oct 2007 | B2 |
7289835 | Mansfield et al. | Oct 2007 | B2 |
7292883 | De Felice et al. | Nov 2007 | B2 |
7341559 | Schulz et al. | Mar 2008 | B2 |
7343186 | Lamego et al. | Mar 2008 | B2 |
D566282 | Al-Ali et al. | Apr 2008 | S |
7356365 | Schurman | Apr 2008 | B2 |
7371981 | Abdul-Hafiz | May 2008 | B2 |
7373193 | Al-Ali et al. | May 2008 | B2 |
7377794 | Al-Ali et al. | May 2008 | B2 |
7395158 | Monfre et al. | Jul 2008 | B2 |
7415297 | Al-Ali et al. | Aug 2008 | B2 |
7438683 | Al-Ali et al. | Oct 2008 | B2 |
7483729 | Al-Ali et al. | Jan 2009 | B2 |
D587657 | Al-Ali et al. | Mar 2009 | S |
7500950 | Al-Ali et al. | Mar 2009 | B2 |
7509494 | Al-Ali | Mar 2009 | B2 |
7510849 | Schurman et al. | Mar 2009 | B2 |
7514725 | Wojtczuk et al. | Apr 2009 | B2 |
7519406 | Blank et al. | Apr 2009 | B2 |
D592507 | Wachman et al. | May 2009 | S |
7530942 | Diab | May 2009 | B1 |
7593230 | Abul-Haj et al. | Sep 2009 | B2 |
7596398 | Al-Ali et al. | Sep 2009 | B2 |
7606608 | Blank et al. | Oct 2009 | B2 |
7620674 | Ruchti et al. | Nov 2009 | B2 |
D606659 | Kiani et al. | Dec 2009 | S |
7629039 | Eckerbom et al. | Dec 2009 | B2 |
7640140 | Ruchti et al. | Dec 2009 | B2 |
7647083 | Al-Ali et al. | Jan 2010 | B2 |
D609193 | Al-Ali et al. | Feb 2010 | S |
D614305 | Al-Ali et al. | Apr 2010 | S |
7697966 | Monfre et al. | Apr 2010 | B2 |
7698105 | Ruchti et al. | Apr 2010 | B2 |
RE41317 | Parker | May 2010 | E |
RE41333 | Blank et al. | May 2010 | E |
7729733 | Al-Ali et al. | Jun 2010 | B2 |
7761127 | Al-Ali et al. | Jul 2010 | B2 |
7764982 | Dalke et al. | Jul 2010 | B2 |
D621516 | Kiani et al. | Aug 2010 | S |
7791155 | Diab | Sep 2010 | B2 |
RE41912 | Parker | Nov 2010 | E |
7880626 | Al-Ali et al. | Feb 2011 | B2 |
7909772 | Popov et al. | Mar 2011 | B2 |
7919713 | Al-Ali et al. | Apr 2011 | B2 |
7937128 | Al-Ali | May 2011 | B2 |
7937129 | Mason et al. | May 2011 | B2 |
7941199 | Kiani | May 2011 | B2 |
7957780 | Lamego et al. | Jun 2011 | B2 |
7962188 | Kiani et al. | Jun 2011 | B2 |
7976472 | Kiani | Jul 2011 | B2 |
7990382 | Kiani | Aug 2011 | B2 |
8008088 | Bellott et al. | Aug 2011 | B2 |
RE42753 | Kiani-Azarbayjany et al. | Sep 2011 | E |
8028701 | Al-Ali et al. | Oct 2011 | B2 |
8048040 | Kiani | Nov 2011 | B2 |
8050728 | Al-Ali et al. | Nov 2011 | B2 |
RE43169 | Parker | Feb 2012 | E |
8118620 | Al-Ali et al. | Feb 2012 | B2 |
8130105 | Al-Ali et al. | Mar 2012 | B2 |
8182443 | Kiani | May 2012 | B1 |
8190223 | Al-Ali et al. | May 2012 | B2 |
8203438 | Kiani et al. | Jun 2012 | B2 |
8203704 | Merritt et al. | Jun 2012 | B2 |
8219172 | Schurman et al. | Jul 2012 | B2 |
8224411 | Al-Ali et al. | Jul 2012 | B2 |
8229532 | Davis | Jul 2012 | B2 |
8233955 | Al-Ali et al. | Jul 2012 | B2 |
8255026 | Al-Ali | Aug 2012 | B1 |
8265723 | McHale et al. | Sep 2012 | B1 |
8274360 | Sampath et al. | Sep 2012 | B2 |
8280473 | Al-Ali | Oct 2012 | B2 |
8315683 | Al-Ali et al. | Nov 2012 | B2 |
RE43860 | Parker | Dec 2012 | E |
8346330 | Lamego | Jan 2013 | B2 |
8353842 | Al-Ali et al. | Jan 2013 | B2 |
8355766 | MacNeish, III et al. | Jan 2013 | B2 |
8374665 | Lamego | Feb 2013 | B2 |
8388353 | Kiani et al. | Mar 2013 | B2 |
8401602 | Kiani | Mar 2013 | B2 |
8414499 | Al-Ali et al. | Apr 2013 | B2 |
8418524 | Al-Ali | Apr 2013 | B2 |
8428967 | Olsen et al. | Apr 2013 | B2 |
8430817 | Al-Ali et al. | Apr 2013 | B1 |
8437825 | Dalvi et al. | May 2013 | B2 |
8455290 | Siskavich | Jun 2013 | B2 |
8457707 | Kiani | Jun 2013 | B2 |
8471713 | Poeze et al. | Jun 2013 | B2 |
8473020 | Kiani et al. | Jun 2013 | B2 |
8509867 | Workman et al. | Aug 2013 | B2 |
8515509 | Bruinsma et al. | Aug 2013 | B2 |
8523781 | Al-Ali | Sep 2013 | B2 |
D692145 | Al-Ali et al. | Oct 2013 | S |
8571617 | Reichgott et al. | Oct 2013 | B2 |
8571618 | Lamego et al. | Oct 2013 | B1 |
8571619 | Al-Ali et al. | Oct 2013 | B2 |
8577431 | Lamego et al. | Nov 2013 | B2 |
8584345 | Al-Ali et al. | Nov 2013 | B2 |
8588880 | Abdul-Hafiz et al. | Nov 2013 | B2 |
8630691 | Lamego et al. | Jan 2014 | B2 |
8641631 | Sierra et al. | Feb 2014 | B2 |
8652060 | Al-Ali | Feb 2014 | B2 |
8666468 | Al-Ali | Mar 2014 | B1 |
8670811 | O'Reilly | Mar 2014 | B2 |
RE44823 | Parker | Apr 2014 | E |
RE44875 | Kiani et al. | Apr 2014 | E |
8688183 | Bruinsma et al. | Apr 2014 | B2 |
8690799 | Telfort et al. | Apr 2014 | B2 |
8702627 | Telfort et al. | Apr 2014 | B2 |
8712494 | MacNeish, III et al. | Apr 2014 | B1 |
8715206 | Telfort et al. | May 2014 | B2 |
8723677 | Kiani | May 2014 | B1 |
8740792 | Kiani et al. | Jun 2014 | B1 |
8755535 | Telfort et al. | Jun 2014 | B2 |
8755872 | Marinow | Jun 2014 | B1 |
8764671 | Kiani | Jul 2014 | B2 |
8768423 | Shakespeare et al. | Jul 2014 | B2 |
8771204 | Telfort et al. | Jul 2014 | B2 |
8781544 | Al-Ali et al. | Jul 2014 | B2 |
8790268 | Al-Ali | Jul 2014 | B2 |
8801613 | Al-Ali et al. | Aug 2014 | B2 |
8821397 | Al-Ali et al. | Sep 2014 | B2 |
8821415 | Al-Ali et al. | Sep 2014 | B2 |
8830449 | Lamego et al. | Sep 2014 | B1 |
8840549 | Al-Ali et al. | Sep 2014 | B2 |
8852094 | Al-Ali et al. | Oct 2014 | B2 |
8852994 | Wojtczuk et al. | Oct 2014 | B2 |
8897847 | Al-Ali | Nov 2014 | B2 |
8911377 | Al-Ali | Dec 2014 | B2 |
8989831 | Al-Ali et al. | Mar 2015 | B2 |
8998809 | Kiani | Apr 2015 | B2 |
9066666 | Kiani | Jun 2015 | B2 |
9066680 | Al-Ali et al. | Jun 2015 | B1 |
9095316 | Welch et al. | Aug 2015 | B2 |
9106038 | Telfort et al. | Aug 2015 | B2 |
9107625 | Telfort et al. | Aug 2015 | B2 |
9131881 | Diab et al. | Sep 2015 | B2 |
9138180 | Coverston et al. | Sep 2015 | B1 |
9153112 | Kiani et al. | Oct 2015 | B1 |
9192329 | Al-Ali | Nov 2015 | B2 |
9192351 | Telfort et al. | Nov 2015 | B1 |
9195385 | Al-Ali et al. | Nov 2015 | B2 |
9211095 | Al-Ali | Dec 2015 | B1 |
9218454 | Kiani et al. | Dec 2015 | B2 |
9245668 | Vo et al. | Jan 2016 | B1 |
9267572 | Barker et al. | Feb 2016 | B2 |
9277880 | Poeze et al. | Mar 2016 | B2 |
9307928 | Al-Ali et al. | Apr 2016 | B1 |
9323894 | Kiani | Apr 2016 | B2 |
D755392 | Hwang et al. | May 2016 | S |
9326712 | Kiani | May 2016 | B1 |
9392945 | Al-Ali et al. | Jul 2016 | B2 |
9408542 | Kinast et al. | Aug 2016 | B1 |
9436645 | Al-Ali et al. | Sep 2016 | B2 |
9445759 | Lamego et al. | Sep 2016 | B1 |
9474474 | Lamego et al. | Oct 2016 | B2 |
9480435 | Olsen | Nov 2016 | B2 |
9510779 | Poeze et al. | Dec 2016 | B2 |
9517024 | Kiani et al. | Dec 2016 | B2 |
9532722 | Lamego et al. | Jan 2017 | B2 |
9560996 | Kiani | Feb 2017 | B2 |
9579039 | Jansen et al. | Feb 2017 | B2 |
9622692 | Lamego et al. | Apr 2017 | B2 |
D788312 | Al-Ali et al. | May 2017 | S |
9649054 | Lamego et al. | May 2017 | B2 |
9697928 | Al-Ali et al. | Jul 2017 | B2 |
9717458 | Lamego et al. | Aug 2017 | B2 |
9724016 | Al-Ali et al. | Aug 2017 | B1 |
9724024 | Al-Ali | Aug 2017 | B2 |
9724025 | Kiani et al. | Aug 2017 | B1 |
9749232 | Sampath et al. | Aug 2017 | B2 |
9750442 | Olsen | Sep 2017 | B2 |
9750461 | Telfort | Sep 2017 | B1 |
9775545 | Al-Ali et al. | Oct 2017 | B2 |
9778079 | Al-Ali et al. | Oct 2017 | B1 |
9782077 | Lamego et al. | Oct 2017 | B2 |
9787568 | Lamego et al. | Oct 2017 | B2 |
9808188 | Perea et al. | Nov 2017 | B1 |
9839379 | Al-Ali et al. | Dec 2017 | B2 |
9839381 | Weber et al. | Dec 2017 | B1 |
9847749 | Kiani et al. | Dec 2017 | B2 |
9848800 | Lee et al. | Dec 2017 | B1 |
9861298 | Eckerbom et al. | Jan 2018 | B2 |
9861305 | Weber et al. | Jan 2018 | B1 |
9877650 | Muhsin et al. | Jan 2018 | B2 |
9891079 | Dalvi | Feb 2018 | B2 |
9924897 | Abdul-Hafiz | Mar 2018 | B1 |
9936917 | Poeze et al. | Apr 2018 | B2 |
9955937 | Telfort | May 2018 | B2 |
9965946 | Al-Ali et al. | May 2018 | B2 |
D820865 | Muhsin et al. | Jun 2018 | S |
9986952 | Dalvi et al. | Jun 2018 | B2 |
D822215 | Al-Ali et al. | Jul 2018 | S |
D822216 | Barker et al. | Jul 2018 | S |
10010276 | Al-Ali et al. | Jul 2018 | B2 |
10086138 | Novak, Jr. | Oct 2018 | B1 |
10111591 | Dyell et al. | Oct 2018 | B2 |
D833624 | DeJong et al. | Nov 2018 | S |
10123729 | Dyell et al. | Nov 2018 | B2 |
D835282 | Barker et al. | Dec 2018 | S |
D835283 | Barker et al. | Dec 2018 | S |
D835284 | Barker et al. | Dec 2018 | S |
D835285 | Barker et al. | Dec 2018 | S |
10149616 | Al-Ali et al. | Dec 2018 | B2 |
10154815 | Al-Ali et al. | Dec 2018 | B2 |
10159412 | Lamego et al. | Dec 2018 | B2 |
10188348 | Al-Ali et al. | Jan 2019 | B2 |
RE47218 | Al-Ali | Feb 2019 | E |
RE47244 | Kiani et al. | Feb 2019 | E |
RE47249 | Kiani et al. | Feb 2019 | E |
10205291 | Scruggs et al. | Feb 2019 | B2 |
10226187 | Al-Ali et al. | Mar 2019 | B2 |
10231657 | Al-Ali et al. | Mar 2019 | B2 |
10231670 | Blank et al. | Mar 2019 | B2 |
RE47353 | Kiani et al. | Apr 2019 | E |
10279247 | Kiani | May 2019 | B2 |
10292664 | Al-Ali | May 2019 | B2 |
10299720 | Brown et al. | May 2019 | B2 |
10327337 | Schmidt et al. | Jun 2019 | B2 |
10327713 | Barker et al. | Jun 2019 | B2 |
10332630 | Al-Ali | Jun 2019 | B2 |
10383520 | Wojtczuk et al. | Aug 2019 | B2 |
10383527 | Ai-Ali | Aug 2019 | B2 |
10388120 | Muhsin et al. | Aug 2019 | B2 |
D864120 | Forrest et al. | Oct 2019 | S |
10441181 | Telfort et al. | Oct 2019 | B1 |
10441196 | Eckerbom et al. | Oct 2019 | B2 |
10448844 | Al-Ali et al. | Oct 2019 | B2 |
10448871 | Al-Ali et al. | Oct 2019 | B2 |
10456038 | Lamego et al. | Oct 2019 | B2 |
10463340 | Telfort et al. | Nov 2019 | B2 |
10471159 | Lapotko et al. | Nov 2019 | B1 |
10505311 | Al-Ali et al. | Dec 2019 | B2 |
10524738 | Olsen | Jan 2020 | B2 |
10532174 | Al-Ali | Jan 2020 | B2 |
10537285 | Shreim et al. | Jan 2020 | B2 |
10542903 | Al-Ali et al. | Jan 2020 | B2 |
10555678 | Dalvi et al. | Feb 2020 | B2 |
10568553 | O'Neil et al. | Feb 2020 | B2 |
RE47882 | Al-Ali | Mar 2020 | E |
10608817 | Haider et al. | Mar 2020 | B2 |
D880477 | Forrest et al. | Apr 2020 | S |
10617302 | Al-Ali et al. | Apr 2020 | B2 |
10617335 | Al-Ali et al. | Apr 2020 | B2 |
10637181 | Al-Ali et al. | Apr 2020 | B2 |
D887548 | Abdul-Hafiz et al. | Jun 2020 | S |
D887549 | Abdul-Hafiz et al. | Jun 2020 | S |
10667764 | Ahmed et al. | Jun 2020 | B2 |
D890708 | Forrest et al. | Jul 2020 | S |
10721785 | Al-Ali | Jul 2020 | B2 |
10736518 | Al-Ali et al. | Aug 2020 | B2 |
10750984 | Pauley et al. | Aug 2020 | B2 |
D897098 | Al-Ali | Sep 2020 | S |
10779098 | Iswanto et al. | Sep 2020 | B2 |
10827961 | Iyengar et al. | Nov 2020 | B1 |
10828007 | Telfort et al. | Nov 2020 | B1 |
10832818 | Muhsin et al. | Nov 2020 | B2 |
10849554 | Shreim et al. | Dec 2020 | B2 |
10856750 | Indorf | Dec 2020 | B2 |
D906970 | Forrest et al. | Jan 2021 | S |
10918281 | Al-Ali et al. | Feb 2021 | B2 |
10932705 | Muhsin et al. | Mar 2021 | B2 |
10932729 | Kiani et al. | Mar 2021 | B2 |
10939878 | Kiani et al. | Mar 2021 | B2 |
10956950 | Al-Ali et al. | Mar 2021 | B2 |
D916135 | Indorf et al. | Apr 2021 | S |
D917550 | Indorf et al. | Apr 2021 | S |
D917564 | Indorf et al. | Apr 2021 | S |
D917704 | Al-Ali et al. | Apr 2021 | S |
10987066 | Chandran et al. | Apr 2021 | B2 |
10991135 | Al-Ali et al. | Apr 2021 | B2 |
D919094 | Al-Ali et al. | May 2021 | S |
D919100 | Al-Ali et al. | May 2021 | S |
11006867 | Al-Ali | May 2021 | B2 |
D921202 | Al-Ali et al. | Jun 2021 | S |
11024064 | Muhsin et al. | Jun 2021 | B2 |
11026604 | Chen et al. | Jun 2021 | B2 |
D925597 | Chandran et al. | Jul 2021 | S |
D927699 | Al-Ali et al. | Aug 2021 | S |
11076777 | Lee et al. | Aug 2021 | B2 |
11114188 | Poeze et al. | Sep 2021 | B2 |
D933232 | Al-Ali et al. | Oct 2021 | S |
11145408 | Sampath et al. | Oct 2021 | B2 |
11147518 | Al-Ali et al. | Oct 2021 | B1 |
11185262 | Al-Ali et al. | Nov 2021 | B2 |
11191484 | Kiani et al. | Dec 2021 | B2 |
20010034477 | Mansfield et al. | Oct 2001 | A1 |
20010039483 | Brand et al. | Nov 2001 | A1 |
20020010401 | Bushmakin et al. | Jan 2002 | A1 |
20020058864 | Mansfield et al. | May 2002 | A1 |
20020133080 | Apruzzese et al. | Sep 2002 | A1 |
20030013975 | Kiani | Jan 2003 | A1 |
20030018243 | Gerhardt et al. | Jan 2003 | A1 |
20030144582 | Cohen et al. | Jul 2003 | A1 |
20030156288 | Barnum et al. | Aug 2003 | A1 |
20030212312 | Coffin, IV et al. | Nov 2003 | A1 |
20040106163 | Workman, Jr. et al. | Jun 2004 | A1 |
20050055276 | Kiani et al. | Mar 2005 | A1 |
20050234317 | Kiani | Oct 2005 | A1 |
20060073719 | Kiani | Apr 2006 | A1 |
20060189871 | Al-Ali et al. | Aug 2006 | A1 |
20070073116 | Kiani et al. | Mar 2007 | A1 |
20070180140 | Welch et al. | Aug 2007 | A1 |
20070239058 | Krasilchikov et al. | Oct 2007 | A1 |
20070244377 | Cozad et al. | Oct 2007 | A1 |
20080064965 | Jay et al. | Mar 2008 | A1 |
20080094228 | Welch et al. | Apr 2008 | A1 |
20080221418 | Al-Ali et al. | Sep 2008 | A1 |
20090036759 | Ault et al. | Feb 2009 | A1 |
20090093687 | Telfort et al. | Apr 2009 | A1 |
20090095926 | MacNeish, III | Apr 2009 | A1 |
20090247984 | Lamego et al. | Oct 2009 | A1 |
20100004518 | Vo et al. | Jan 2010 | A1 |
20100030040 | Poeze et al. | Feb 2010 | A1 |
20100099964 | O'Reilly et al. | Apr 2010 | A1 |
20100234718 | Sampath et al. | Sep 2010 | A1 |
20100270257 | Wachman et al. | Oct 2010 | A1 |
20110028806 | Merritt et al. | Feb 2011 | A1 |
20110028809 | Goodman | Feb 2011 | A1 |
20110040197 | Welch et al. | Feb 2011 | A1 |
20110082711 | Poeze et al. | Apr 2011 | A1 |
20110087081 | Kiani et al. | Apr 2011 | A1 |
20110118561 | Tari et al. | May 2011 | A1 |
20110120455 | Murphy | May 2011 | A1 |
20110137297 | Kiani et al. | Jun 2011 | A1 |
20110172498 | Olsen et al. | Jul 2011 | A1 |
20110180067 | Avni | Jul 2011 | A1 |
20110230733 | Al-Ali | Sep 2011 | A1 |
20120123231 | O'Reilly | May 2012 | A1 |
20120165629 | Merritt et al. | Jun 2012 | A1 |
20120209084 | Olsen et al. | Aug 2012 | A1 |
20120226117 | Lamego et al. | Sep 2012 | A1 |
20120283524 | Kiani et al. | Nov 2012 | A1 |
20130023775 | Lamego et al. | Jan 2013 | A1 |
20130041591 | Lamego | Feb 2013 | A1 |
20130060147 | Welch et al. | Mar 2013 | A1 |
20130096405 | Garfio | Apr 2013 | A1 |
20130296672 | O'Neil et al. | Nov 2013 | A1 |
20130345921 | Al-Ali et al. | Dec 2013 | A1 |
20140166076 | Kiani et al. | Jun 2014 | A1 |
20140180160 | Brown et al. | Jun 2014 | A1 |
20140187973 | Brown et al. | Jul 2014 | A1 |
20140275871 | Lamego et al. | Sep 2014 | A1 |
20140275872 | Merritt et al. | Sep 2014 | A1 |
20140316217 | Purdon et al. | Oct 2014 | A1 |
20140316218 | Purdon et al. | Oct 2014 | A1 |
20140323897 | Brown et al. | Oct 2014 | A1 |
20140323898 | Purdon et al. | Oct 2014 | A1 |
20150005600 | Blank et al. | Jan 2015 | A1 |
20150011907 | Purdon et al. | Jan 2015 | A1 |
20150073241 | Lamego | Mar 2015 | A1 |
20150080754 | Purdon et al. | Mar 2015 | A1 |
20150099950 | Al-Ali et al. | Apr 2015 | A1 |
20150273165 | Hadash | Oct 2015 | A1 |
20160196388 | Lamego | Jul 2016 | A1 |
20160283665 | Sampath et al. | Sep 2016 | A1 |
20160367173 | Dalvi et al. | Dec 2016 | A1 |
20170024748 | Haider | Jan 2017 | A1 |
20170173632 | Al-Ali | Jun 2017 | A1 |
20170251974 | Shreim et al. | Sep 2017 | A1 |
20170311891 | Kiani et al. | Nov 2017 | A1 |
20180242926 | Muhsin et al. | Aug 2018 | A1 |
20180247353 | Al-Ali et al. | Aug 2018 | A1 |
20180247712 | Muhsin et al. | Aug 2018 | A1 |
20180256087 | Al-Ali et al. | Sep 2018 | A1 |
20180310823 | Al-Ali et al. | Nov 2018 | A1 |
20190046079 | Reed | Feb 2019 | A1 |
20190117070 | Muhsin et al. | Apr 2019 | A1 |
20190239787 | Pauley et al. | Aug 2019 | A1 |
20190320906 | Olsen | Oct 2019 | A1 |
20190374713 | Kiani et al. | Dec 2019 | A1 |
20200060869 | Telfort et al. | Feb 2020 | A1 |
20200111552 | Ahmed | Apr 2020 | A1 |
20200113435 | Muhsin | Apr 2020 | A1 |
20200113488 | Al-Ali et al. | Apr 2020 | A1 |
20200113496 | Scruggs et al. | Apr 2020 | A1 |
20200113497 | Triman et al. | Apr 2020 | A1 |
20200113520 | Abdul-Hafiz et al. | Apr 2020 | A1 |
20200138288 | Al-Ali et al. | May 2020 | A1 |
20200138368 | Kiani et al. | May 2020 | A1 |
20200163597 | Dalvi et al. | May 2020 | A1 |
20200196877 | Vo et al. | Jun 2020 | A1 |
20200253474 | Muhsin et al. | Aug 2020 | A1 |
20200253544 | Belur Nagaraj et al. | Aug 2020 | A1 |
20200268990 | Ash | Aug 2020 | A1 |
20200275841 | Telfort et al. | Sep 2020 | A1 |
20200288983 | Telfort et al. | Sep 2020 | A1 |
20200321793 | Al-Ali et al. | Oct 2020 | A1 |
20200329983 | Al-Ali et al. | Oct 2020 | A1 |
20200329984 | Al-Ali et al. | Oct 2020 | A1 |
20200329993 | Al-Ali et al. | Oct 2020 | A1 |
20200330037 | Al-Ali et al. | Oct 2020 | A1 |
20210022628 | Telfort et al. | Jan 2021 | A1 |
20210104173 | Pauley et al. | Apr 2021 | A1 |
20210113121 | Diab et al. | Apr 2021 | A1 |
20210117525 | Kiani et al. | Apr 2021 | A1 |
20210118581 | Kiani et al. | Apr 2021 | A1 |
20210121582 | Krishnamani et al. | Apr 2021 | A1 |
20210146079 | Alizoti | May 2021 | A1 |
20210161465 | Barker et al. | Jun 2021 | A1 |
20210236729 | Kiani et al. | Aug 2021 | A1 |
20210256267 | Ranasinghe et al. | Aug 2021 | A1 |
20210256835 | Ranasinghe et al. | Aug 2021 | A1 |
20210275101 | Vo et al. | Sep 2021 | A1 |
20210290060 | Ahmed | Sep 2021 | A1 |
20210290072 | Forrest | Sep 2021 | A1 |
20210290080 | Ahmed | Sep 2021 | A1 |
20210290120 | Al-Ali | Sep 2021 | A1 |
20210290177 | Novak, Jr. | Sep 2021 | A1 |
20210290184 | Ahmed | Sep 2021 | A1 |
20210296008 | Novak, Jr. | Sep 2021 | A1 |
20210330228 | Olsen et al. | Oct 2021 | A1 |
20210386382 | Olsen et al. | Dec 2021 | A1 |
Number | Date | Country |
---|---|---|
WO 2017141033 | Aug 2017 | WO |
WO-2021194880 | Sep 2021 | WO |
WO 2021262877 | Dec 2021 | WO |
Entry |
---|
International Search Report and Written Opinion received in PCT Application No. PCT/US2021/038733 dated Oct. 20, 2021. |
Number | Date | Country | |
---|---|---|---|
20210402110 A1 | Dec 2021 | US |
Number | Date | Country | |
---|---|---|---|
63071310 | Aug 2020 | US | |
63044269 | Jun 2020 | US |